Novel tau fragments in cerebrospinal fluid: relation to tangle pathology and cognitive decline in Alzheimer’s disease
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
Tau is an axonal microtubule-binding protein. Tau pathology in brain and increased tau concentration in the cerebrospinal fluid (CSF) are hallmarks of Alzheimer's disease (AD). Most of tau in CSF is present as fragments. We immunoprecipitated tau from CSF and identified several endogenous peptides ending at amino acid (aa) 123 or 224 using high-resolution mass spectrometry. We raised neo-epitope-specific antibodies against tau fragments specifically ending at aa 123 and 224, respectively. With these antibodies, we performed immunohistochemistry on brain tissue and designed immunoassays measuring N-123, N-224, and x-224 tau. Immunoassays were applied to soluble brain fractions from pathologically confirmed subjects (81 AD patients, 33 controls), CSF from three cross-sectional and two longitudinal cohorts (a total of 133 AD, 38 MCI, 20 MCI-AD, 31 PSP, 15 CBS patients, and 91 controls), and neuronally- and peripherally-derived extracellular vesicles (NDEVs and PDEVs, respectively) in serum from four AD patients and four controls. Anti-tau 224 antibody stained neurofibrillary tangles and neuropil threads, while anti-tau 123 only showed weak cytoplasmic staining in AD. N-224 tau was lower in the AD soluble brain fraction compared to controls, while N-123 tau showed similar levels. N-224 tau was higher in AD compared to controls in all CSF cohorts (p < 0.001), but not N-123 tau. Decrease in cognitive performance and conversion from MCI to AD were associated with increased baseline CSF levels of N-224 tau (p < 0.0001). N-224 tau concentrations in PSP and CBS were significantly lower than in AD (p < 0.0001) and did not correlate to t-tau and p-tau. In a longitudinal cohort, CSF N-224 tau levels were stable over 6 months, with no significant effect of treatment with AChE inhibitors. N-224 tau was present in NDEVs, while N-123 tau showed comparable concentrations in both vesicle types. We suggest that N-123 tau is produced both in CNS and PNS and represents a general marker of tau metabolism, while N-224 tau is neuron-specific, present in the tangles, secreted in CSF, and upregulated in AD, suggesting a link between tau cleavage and propagation, tangle pathology, and cognitive decline.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures









Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For example, the CSF t-tau immunoassay used here relies on a combination of monoclonal antibodies with epitopes in the mid-protein region.In contrast, the plasma t-tau assay detects epitopes going from the N-terminal region to the more distal amino acid 224.39”
From Plasma Tau and Neurofilament Light in Frontotemporal Lobar Degeneration and Alzheimer Disease (2021) · cites this paper as [39]
Experimental — accuracy not yet measuredIn the citing paper
“In AD, tau becomes truncated and hyperphosphorylated (3), which can increase the risk for tau to aggregate into the paired helical filaments (PHF) that are found in neurofibrillary tangles (NFT) and neuropil treads in the brains of patients with AD (1).”
From Aβ deposition is associated with increases in soluble and phosphorylated tau that precede a positive tau PET in Alzheimer's disease (2020) · cites this paper as [3]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915
Kok, J. S., Berg, I. J., & Scherder, E. J. A. (2013) · Dementia and Geriatric Cognitive Disorders Extra · doi:10.1159/000353441 · Cited by 20,589
McKhann, G. M., Knopman, D. S., Chertkow, H., Hyman, B. T., Jack, C. R., Kawas, C. H., Klunk, W. E., Koroshetz, W. J., Manly, J. J., Mayeux, R., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.03.005 · Cited by 18,657
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
Mild cognitive impairment as a diagnostic entity
Petersen, R. C. (2004) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2004.01388.x · Cited by 7,864
A new rating scale for Alzheimer's disease
(1984) · American Journal of Psychiatry · doi:10.1176/ajp.141.11.1356 · Cited by 4,175
Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria
Dubois, B., Feldman, H. H., Jacova, C., Hampel, H., Molinuevo, J. L., Blennow, K., DeKosky, S. T., Gauthier, S., Selkoe, D., Bateman, R., et al. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70090-0 · Cited by 3,321
Self-citationScheltens, P., Blennow, K., Breteler, M. M. B., de Strooper, B., Frisoni, G. B., Salloway, S., & Van der Flier, W. M. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01124-1 · Cited by 3,125
Self-citationOlsson, B., Lautner, R., Andreasson, U., Öhrfelt, A., Portelius, E., Bjerke, M., Hölttä, M., Rosén, C., Olsson, C., Strobel, G., et al. (2016) · The Lancet Neurology · doi:10.1016/s1474-4422(16)00070-3 · Cited by 2,049
Self-citationCriteria for the diagnosis of corticobasal degeneration
Armstrong, M. J., Litvan, I., Lang, A. E., Bak, T. H., Bhatia, K. P., Borroni, B., Boxer, A. L., Dickson, D. W., Grossman, M., Hallett, M., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31827f0fd1 · Cited by 1,904 · cited 6×
“Aβsubjects were 15 in the PSP and seven in the CBS group.”
BackgroundInfluential
Cited by
Items 101–187 of 187
Disease-modifying strategies in primary tauopathies
Rösler, T. W., Costa, M., & Höglinger, G. U. (2019) · Neuropharmacology · doi:10.1016/j.neuropharm.2019.107842 · Cited by 18
Hirota, Y., Sakakibara, Y., Morishima, M., Sano, T., Hara, M., Arakawa, A., Takao, M., Murayama, S., Saito, Y., Sekiya, M., et al. (2025) · Cell Reports · doi:10.1016/j.celrep.2025.116203 · Cited by 17
Cicognola, C., Hansson, O., Scheltens, P., Kvartsberg, H., Zetterberg, H., Teunissen, C. E., & Blennow, K. (2021) · Alzheimer s Research & Therapy · doi:10.1186/s13195-020-00756-6 · Cited by 17
Self-citationAnti-tau antibodies targeting a conformation-dependent epitope selectively bind seeds
Hitt, B. D., Gupta, A., Singh, R., Yang, T., Beaver, J. D., Shang, P., White, C. L., Joachimiak, L. A., & Diamond, M. I. (2023) · doi:10.1101/2023.05.04.539475 · Cited by 15
Kimura, T., Sato, H., Kano, M., Tatsumi, L., & Tomita, T. (2023) · FEBS Open Bio · doi:10.1002/2211-5463.13667 · Cited by 15
Tauopathy-Associated Tau Fragment Ending at Amino Acid 224 Is Generated by Calpain-2 Cleavage
Cicognola, C., Şatır, T. M., Brinkmalm, G., Matečko‐Burmann, I., Agholme, L., Bergström, P., Becker, B., Zetterberg, H., Blennow, K., & Höglund, K. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191130 · Cited by 14
Self-citationValidation of Tau Antibodies for Use in Western Blotting and ImmunohistochemistryPreprint
Ellis, M. J., Lekka, C., Tulmin, H., O'Brien, D. P., Dhayal, S., Zeissler, M., Knudsen, J. G., Kessler, B. M., Morgan, N. G., Todd, J. A., et al. (2023) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2023.04.13.536711 · Cited by 14
Truncating tau reveals different pathophysiological actions of oligomers in single neurons
Hill, E., Karikari, T. K., Lantero‐Rodriguez, J., Zetterberg, H., Blennow, K., Richardson, M. J. E., & Wall, M. J. (2021) · Communications Biology · doi:10.1038/s42003-021-02791-x · Cited by 13
Self-citationA call for better understanding of target engagement in Tau antibody development
Bespalov, A., Courade, J., Khiroug, L., Terstappen, G. C., & Wang, Y. (2022) · Drug Discovery Today · doi:10.1016/j.drudis.2022.103338 · Cited by 13
Loeffler, D. A., Aasly, J. O., LeWitt, P. A., & Coffey, M. P. (2019) · Journal of Parkinson s Disease · doi:10.3233/jpd-191630 · Cited by 13
NT1-Tau Is Increased in CSF and Plasma of CJD Patients, and Correlates with Disease Progression
Mengel, D., Mok, T. H., Nihat, A., Liu, W., Rissman, R. A., Galasko, D., Zetterberg, H., Mead, S., Collinge, J., & Walsh, D. M. (2021) · Cells · doi:10.3390/cells10123514 · Cited by 12
Self-citationFrost, B. E., Rowe, J. B., Akinyemi, R., Abisambra, J. F., Ashton, N. J., Brendel, M., Buée, L., Butler, D., Carrillo, M. C., Chung, P. S., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70078 · Cited by 12
Self-citationThe neuropathological landscape of Hispanic and non-Hispanic White decedents with Alzheimer disease
Scalco, R., Saito, N. H., Beckett, L. A., Nguyen, M.-L., Huie, E. Z., Wang, H.-P., Flaherty, D., Honig, L. S., DeCarli, C. S., Rissman, R. A., et al. (2023) · Acta Neuropathologica Communications · doi:10.1186/s40478-023-01574-1 · Cited by 12
Rizzi, L., & Grinberg, L. T. (2024) · Acta Neuropathologica Communications · doi:10.1186/s40478-024-01744-9 · Cited by 12
Contributions of Molecular and Optical Techniques to the Clinical Diagnosis of Alzheimer’s Disease
Bistaffa, E., Tagliavini, F., Matteini, P., & Moda, F. (2020) · Brain Sciences · doi:10.3390/brainsci10110815 · Cited by 12
Tau biomarkers for neurodegenerative diseases: Current state and perspectives
Vacchi, E., Ruíz‐Barrio, I., & Melli, G. (2025) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2025.107772 · Cited by 12
Argentati, C., Tortorella, I., Bazzucchi, M., Emiliani, C., Morena, F., & Martino, S. (2020) · Journal of Personalized Medicine · doi:10.3390/jpm10030115 · Cited by 11
Hantke, N. C., Kaye, J., Mattek, N., Wu, C.-Y., Dodge, H. H., Beattie, Z., & Woltjer, R. (2023) · PLOS ONE · doi:10.1371/journal.pone.0286812 · Cited by 10
Semorinemab Pharmacokinetics and The Effect on Plasma Total Tau Pharmacodynamics in Clinical Studies
Ramakrishnan, V., Bender, B. C., Langenhorst, J. B., Magnusson, M. O., Dolton, M. J., Shim, J., Fuji, R. N., Monteiro, C., Teng, E., Kassir, N., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.146 · Cited by 10
Nabizadeh, F. (2024) · Neurology Letters · doi:10.61186/nl.3.2.14 · Cited by 10
The Fate of Tau Aggregates Between Clearance and Transmission
Seitkazina, A., Kim, K. H., Fagan, E., Sung, Y., Kim, Y. K., & Lim, S. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.932541 · Cited by 10
Neuschmid, S., Schallerer, C., Ehrlich, B. E., & McGuone, D. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189245 · Cited by 9
Novel concepts in the pathogenesis of hydrocephalus
Figueiredo, M. V. D., Alexiou, G. Α., Laube, K. A. C., Manfroi, G., & Rehder, R. (2023) · Child s Nervous System · doi:10.1007/s00381-023-05891-7 · Cited by 9
Development and validation of a novel Simoa assay for NPTX2 in Alzheimer's disease and Down syndrome
Sauer, M., Gomes, B. F., Shahrouki, P., Lantero‐Rodriguez, J., Montoliu‐Gaya, L., Camporesi, E., Belbin, O., Alcolea, D. A., Kumar, A., Sharma, M., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70241 · Cited by 8
Self-citationHoney, M. I. J., Hok‐A‐Hin, Y. S., Thijssen, E. H., Cousins, K. A. Q., van der Weijden, B., Veld, L. I. ‘., Stoops, E., de Boer, S. C. M., Duits, F. H., Houwer, J. F. H. D., et al. (2026) · Nature Medicine · doi:10.1038/s41591-026-04341-6 · Cited by 8
Alzheimer’s Disease-Related Cerebrospinal Fluid Biomarkers in Progressive Supranuclear Palsy
Ishiguro, T., & Kasuga, K. (2024) · Brain Sciences · doi:10.3390/brainsci14090859 · Cited by 8
Klenner, M. A., Fraser, B. H., Moon, V., Evans, B. J., Massi, M., & Pascali, G. (2020) · European Journal of Inorganic Chemistry · doi:10.1002/ejic.202000433 · Cited by 8
Increased Noradrenaline as an Additional Cerebrospinal Fluid Biomarker in PSP-Like Parkinsonism
Cerroni, R., Liguori, C., Stefani, A., Conti, M., Garasto, E., Pierantozzi, M., Mercuri, N. B., Bernardini, S., Fucci, G., & Massoud, R. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.00126 · Cited by 8
Yim, S., Park, S., Lim, K., Kang, H., Shin, D., Jo, H., Jang, H., Weiner, M. W., Zetterberg, H., Blennow, K., et al. (2025) · Neurology · doi:10.1212/wnl.0000000000213954 · Cited by 7
Self-citationTau protein aggregation: A therapeutic target for neurodegenerative diseases
Duggal, A., Mahindru, D., Baghel, K., Mehrotra, S., & Prajapati, V. K. (2025) · Advances in protein chemistry and structural biology · doi:10.1016/bs.apcsb.2024.11.012 · Cited by 5
Weidling, I. W., Preiss, C. N., Chancellor, S. E., Srivastava, G. P., Gibilisco, L., Lin, G., Brennan, M. S., Lee, J. Y., Roth, L. M., Morozova, O., et al. (2025) · Acta Neuropathologica Communications · doi:10.1186/s40478-025-02000-4 · Cited by 5
Plasma NT1 tau is associated with hypometabolism in Alzheimer’s disease continuum
Lalaklou, Z. G., Ghahjavarestani, A. M., Pishkari, Y., & Emami, D. (2024) · Neurology Letters · doi:10.61186/nl.3.2.8 · Cited by 6
Recent trends of extracellular vesicles for therapeutic intervention of brain-related diseases
Handa, M., Reddy, G. A., Panicker, N., Singh, S., & Ruwali, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85544-0.00007-1 · Cited by 5
Molecular profiling in Parkinsonian syndromes: CSF biomarkers
Paoletti, F. P., Gaetani, L., & Parnetti, L. (2020) · Clinica Chimica Acta · doi:10.1016/j.cca.2020.03.002 · Cited by 5
Self-citationZhou, X., Lu, Y., Cui, X., Li, N., Wei, Y., Li, H., & Feng, L. (2025) · Analytical Chemistry · doi:10.1021/acs.analchem.5c02255 · Cited by 4
Jiang, H., Esparza, T. J., Kummer, T. T., & Brody, D. L. (2021) · PLoS ONE · doi:10.1371/journal.pone.0259335 · Cited by 4
Targeting alpha-synuclein or tau for treating neurodegenerative movement disorders
Cuina, M. L., & Meissner, W. G. (2022) · Revue Neurologique · doi:10.1016/j.neurol.2022.03.010 · Cited by 4
Yim, S., Park, S., Lim, K. Y., Kang, H., Shin, D., Jang, H., Weiner, M. W., Zetterberg, H., Blennow, K., González‐Ortiz, F., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01870-z · Cited by 3
Self-citationSECmeres outperform extracellular vesicles as potential blood RNA biomarkers for Alzheimer’s disease
Gonzalez‐Kozlova, E., Tichkule, S., Nose, Y., Chen, T.-Y., Reznik, E., Santiago, J. V., Korrapati, A., Soleymani, T., Kosoy, R., Figueiredo, I., et al. (2026) · Nature Communications · doi:10.1038/s41467-026-74541-8 · Cited by 3
Lee, J., Olafson, E., Toth, B., Casavant, E., Schauer, S. P., Bittner, T., Meyer, M. R., Verghese, P. B., Venkatesh, V., West, T., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71604 · Cited by 3
Advances in Alzheimer's Disease Biomarkers
Li, K., Gao, Y., Liu, M., & Chen, Y. (2024) · Current Alzheimer Research · doi:10.2174/0115672050366767241223050957 · Cited by 3
Höglinger, G. U., Vandenberghe, W., Woitalla, D., Corvol, J., Tricht, H. L. G. V., Ewen, C., Steen, B. V. D., Mesa, I. R., Germani, M., Garric, E., et al. (2026) · BMJ Neurology Open · doi:10.1136/bmjno-2025-001396 · Cited by 2
Mohammadi, S., Rafii‐Tabar, H., & Sasanpour, P. (2022) · Computer Methods and Programs in Biomedicine · doi:10.1016/j.cmpb.2022.106913 · Cited by 2
Neurotheranostics in Alzheimer's Disease: Current concepts and experimental strategies
Yanagisawa, D., Ohgita, T., Kawashima, H., Yoshikawa, H., Saito, H., Tooyama, I., & Takata, K. (2026) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2026.109084 · Cited by 1
Яхьяевич, Я. Н., & Vagabov, N. M. (2009) · VESTNIK OF ASTRAKHAN STATE TECHNICAL UNIVERSITY SERIES MARINE ENGINEERING AND TECHNOLOGIES · Cited by 1
Role of anandamide in Alzheimer's disease
Vera, D. M., & Tambaro, S. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-19081-0.00014-7 · Cited by 1
Biomarkers of Neurodegenerative Diseases: A Review
Igorevna, B. E. (2022) · Techniques in Neurosurgery & Neurology · doi:10.31031/tnn.2022.05.000606 · Cited by 1
Wojdała, A. L., Bellomo, G., Gaetani, L., Shan, D., Parnetti, L., & Chiasserini, D. (2023) · medRxiv · doi:10.1101/2023.06.08.23291128 · Cited by 1
Self-citationKokje, E. (2023) · heiDOK (Heidelberg University) · doi:10.11588/heidok.00033296 · Cited by 1
Caroux, E. (2019) · theses.fr (ABES) · doi:10.70675/35d706bfz0d1bz440ezac4bz7fd4138464f8 · Cited by 1
Jacquemin, C. (2023) · theses.fr (ABES) · doi:10.70675/574d02aaz56daz485fz843dz68565d474db9 · Cited by 1
Cerebrospinal fluid biomarkers and cognition in older adults
Rådestig, M. A. (2021)
Modulation of neuronal function by tau, alpha synuclein or carbon dioxide
Hill, E. (2026) · Warwick Research Archive Portal (University of Warwick) · doi:10.82444/warw.33830401
Vésicules extracellulaires : actrices de la propagation de la pathologie tau dans les tauopathies
Leroux, É. (2021) · theses.fr (ABES) · doi:10.70675/3318b243z20aez4b6bzace8zda153701cc2b
Proximity extension assay-based proteomic studies in Alzheimer’s disease
Yaka, E. C., & Genç, Ş. (2024) · Turkish Journal Of Neurology · doi:10.55697/tnd.2024.96
Arastoo, M., Penny, L. K., Lofthouse, R. A., Hitchcock, A., Moelders, A., Szalma, S., Porter, A. J., Palliyil, S., Harrington, C. R., & Wischik, C. M. (2025) · Scientific Reports · doi:10.1038/s41598-025-25864-x
Mengel, D., Liu, W., Glynn, R. J., Selkoe, D. J., Strydom, A., Lai, F., Rosas, H. D., Torres, A., Patsiogiannis, V., Skotko, B. G., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12010620
Additional file 6 of Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26751392
Self-citationAdditional file 5 of Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26751389
Self-citationMengel, D., Liu, W., Glynn, R. J., Selkoe, D. J., Strydom, A., Lai, F., Rosas, H. D., Torres, A., Patsiogiannis, V., Skotko, B. G., et al. (2020) · Figshare · doi:10.6084/m9.figshare.12010614
Simrén, J., Brum, W. S., Ashton, N. J., Benedet, A. L., Karikari, T. K., Kvartsberg, H., Sjons, E., Lussier, F. Z., Chamoun, M., Stevenson, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.22605773
Self-citationAdditional file 3 of Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26751383
Self-citationAdditional file 8 of Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26751398
Self-citationAdditional file 1 of Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26333190
Self-citationAdditional file 7 of Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26751395
Self-citationScalco, R., Saito, N., Beckett, L. A., Nguyen, M.-L., Huie, E. Z., Wang, H.-P., Flaherty, D., Honig, L. S., DeCarli, C. S., Rissman, R. A., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26600926
Additional file 2 of Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26333445
Self-citationCicognola, C., Hansson, O., Scheltens, P., Kvartsberg, H., Zetterberg, H., Teunissen, C. E., & Blennow, K. (2021) · Figshare · doi:10.6084/m9.figshare.13787431
Self-citationAdditional file 4 of Tau protein profiling in tauopathies: a human brain study
Lantero‐Rodriguez, J., Camporesi, E., Montoliu‐Gaya, L., Gobom, J., Piotrowska, D., Olsson, M., Matečko‐Burmann, I., Becker, B., Brinkmalm, A., Burmann, B. M., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26751386
Self-citationVerelst, J. (2023) · Lirias (KU Leuven)
Emeršič, A. (2024) · Repository of the University of Ljubljana (University of Ljubljana)
Martinisi, A. (2020) · edoc (University of Basel)
Exploring biomarkers for parkinsonian diseases and disease modification trials
Vijiaratnam, N. (2024) · UCL Discovery (University College London)
Batchelor, B. (2023) · ePrints Soton (University of Southampton)
Investigation of Formation of Pathological Tau Species and Their Neurotoxicity.
Pampuščenko, K. (2021) · Lithuanian University of Health Sciences
Van, K. T. (2025) · theses.fr (ABES) · doi:10.70675/32a1a6cez5dd3z42c0za2eaz2e57807081a6
Investigating the Effects of N-Terminal Tau Truncation in the Pathogenesis of Alzheimer's Disease
Sallean, A. (2026) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/jthg-ge75
Tau368 improves p-tau diagnostic accuracy for FTLD-tau from FTLD-TDP
Kac, P. R., Cousins, K. A. Q., Szadziewska, A., Shaw, L. M. J., Turton, M., Deerlin, V. M. V., Harrison, P., Zetterberg, H., Wolk, D. A., McMillan, C. T., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03042-1
Self-citationTau-mediated Mechanisms in Alzheimerʼs Disease Pathogenesis
Narayanappa, T. S., Ananthanarayana, V., & Chinnathambi, S. (2026) · Molecular Neurobiology · doi:10.1007/s12035-026-06057-7
Tau spreading coordinates intercellular lipid flux enhancing neuronal resilience to lipid toxicityPreprint
Oliveras, A., Ibatici, D., Calvo‐Noriega, M., Mastrobuoni, G., Forbes, M., Padilla, L. S., Aykul, M., Horvatović, K., Rusu, M.-C., Patsonis, M., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.07.30.741734
Differential aggregation and seeding of tau microtubule-binding region fragments in vitro
Kim, M.-S., Hwang, S.-J., Kim, D., & Yoon, S.-Y. (2026) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2026.154575
Epitope placement tunes CSF tau biomarkers: Comparison of P-tau217 and BD-tau designs
Gleerup, H. S., Musaeus, C. S., Santos, C., Kvartsberg, H., Harrison, P., Turton, M., Zetterberg, H., Frederiksen, K. S., Hasselbalch, S. G., Simonsen, A. H., et al. (2026) · Molecular Neurodegeneration Advances · doi:10.1186/s44477-026-00050-z
Self-citationPush–pull hypothesis of Alzheimer's disease
Townsend, M. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71721
Metadata
- Authors
- Cicognola, C., Brinkmalm, G., Wahlgren, J., Portelius, E., Gobom, J., Cullen, N. C., Hansson, O., Parnetti, L., Constantinescu, R., Wildsmith, K., Chen, H.-H., Beach, T. G., Lashley, T., Zetterberg, H., Blennow, K., & Höglund, K.
- Affiliations
- University of Gothenburg (SE)
- Sahlgrenska University Hospital (SE)
- University of Pennsylvania (US)
- Lund University (SE)
- University of Perugia (IT)
- Genentech (US)
- Banner Sun Health Research Institute (US)
- National Hospital for Neurology and Neurosurgery (GB)
- Corresponding author
- Cicognola, Claudia
- ORCID
- Venue
- Acta Neuropathologica
- Published
- 2018-12-13
- Volume
- 137
- Issue
- 2
- Pages
- 279-296
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- PMC
- PMC6514201
- OpenAlex
- W2904580289
- Cited by
- 168
- References
- 44
- Citations by year
- 2026: 11 · 2025: 15 · 2024: 18 · 2023: 23 · 2022: 18 · 2021: 29 · 2020: 36 · 2019: 17
- FWCI
- 14.06
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Acta Neuropathologica (publishedVersion, cc-by)
- Europe PMC (PubMed Central) (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Vetenskapsrådet (-)
- European Research Council (-)
- Torsten Söderbergs Stiftelse (-)
- Knut och Alice Wallenbergs Stiftelse (-)
- Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (-)
- Stiftelsen för Gamla Tjänarinnor (-)
- Ågrens Stiftelse (-)
- Swedish Alzheimer's Foundation (-)
- Swedish Brain Foundation (-)
- National Institute of Neurological Disorders and Stroke (U24 NS072026)
- National Institute on Aging (P30 AG19610)
- Arizona Department of Health Services (211002)
- Arizona Biomedical Research Commission (4001, 0011, 05-901, 1001)
- Michael J. Fox Foundation for Parkinson's Research (-)
- Reta Lila Weston Institute for Neurological Studies (-)
- Progressive Supranuclear Palsy Association (-)
- Alzheimer's Research UK (-)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- cerebrospinal fluid biomarkers, Alzheimer's disease, neurofibrillary tangles, cognitive decline, mild cognitive impairment, extracellular vesicles, neurofibrillary pathology, tau phosphorylation, amyloid-beta, prion protein, anti-tau antibodies, immunoassay, AChE inhibitors
- MeSH terms
- Aged, Alzheimer Disease, Brain, Female, Humans, Male, Peptide Fragments, Cohort Studies, Biomarkers, Amyloid beta-Peptides, tau Proteins, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.